Martinsried/Munich, 26 September 2016. Medigene AG (MDG1, Frankfurt, Prime Standard) announces its participation at five upcoming national and international scientific, investor and business development conferences:
• OktoberINVESTfest, 5th Annual Investors Conference
Date: 28 September 2016
Location: New York, USA
Dave Lemus, Medigene’s COO, will give a company presentation.
• Adoptive T-Cell Therapy Summit
Date: 10 - 11 October 2016
Location: London, UK
Prof. Dr. Dolores Schendel, Medigene’s CEO/CSO, will give a talk on the topic: “Mind the gap and fill the need: TCR cell therapies for patients with different MHCs and diverse forms of cancer.”
• Osaka Partnering / BioJapan 2016
Date: 11 - 14 October 2016
Location: Osaka and Yokohama, Japan
• Forum Gesundheitsindustrie Baden-Württemberg
Date: 13 October 2016
Location: Heidelberg, Germany
Dr. Dr. Olav Zilian, Medigenes SVP Corporate Development
will give a talk on the topic: “Innovative T-cell therapy with Medigene’s TCR platform ".
• 6. Equity Forum 2016 on Cancer Immunotherapy
Date: 26 October 2016
Location: Heilbronn, Germany
Prof. Dr. Dolores Schendel, Medigene’s CEO/CSO, will hold a presentation on the latest developments in the field of immunotherapies.
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies.
For more information, please visit www.medigene.com
